Form 4: X4 Pharmaceuticals Director Alison Frances Lawton Acquires 45,000 Shares of Common Stock

Alison Frances Lawton, a director at X4 Pharmaceuticals, acquired 45,000 shares of common stock on June 10, 2024, as part of a restricted stock unit (RSU) grant.

Summary

• On June 10, 2024, Alison Frances Lawton, a director of X4 Pharmaceuticals, acquired 45,000 shares of common stock.
• The acquisition was part of a restricted stock unit (RSU) grant, awarded as an annual award for service on the Board of Directors.
• The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date.
• The RSUs will also vest in full upon the occurrence of a change in control of the Issuer.
• Following the transaction, Lawton directly owns 96,667 shares of X4 Pharmaceuticals common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by a director is generally a good sign, but it's part of a standard compensation package.

Positives

• The acquisition of shares by a director signals confidence in the company's future.
• The vesting conditions tied to board service and a potential change in control align the director's interests with those of the shareholders.

Future Outlook

The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of shares by a director can positively influence shareholder sentiment.

Key Dates